MSLE

Satellos Bioscience Inc. Common Stock NASDAQ Listed May 10, 2024

Healthcare ·Medical - Pharmaceuticals ·CA · satellos.com

$7.14

Mkt Cap $9.2M

52w Low $4.52 29.5% of range 52w High $13.39

50d MA $8.18 200d MA $7.13

P/E (TTM) 3.8x

EV/EBITDA -1.4x

P/B 1.6x

Debt/Equity 0.0x

ROE —

P/FCF -3.9x

RSI (14) —

ATR (14) —

Beta 1.08

50d MA $8.18

200d MA $7.13

Avg Volume 81.6K

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

SIC Code

2834

CIK (SEC)

1421642

Phone

1 647 660 1780

Royal Bank Plaza · Toronto, ON M5J 2J1 · CA

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 27, 2026	AMC	-0.36	-0.47	-30.6%	6.19	+0.3%	-4.5%	-9.0%	-2.4%	-5.2%	-8.7%	—
Nov 14, 2025	AMC	-0.33	-0.36	-11.2%	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	Guggenheim	Initiates	Buy	$23	$7.16	$7.20	+0.6%	+6.3%	+1.5%	+11.0%	+9.6%	+16.8%
Mar 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.19	$6.21	+0.3%	-4.5%	-9.0%	-2.4%	-5.2%	-8.7%

Data updated apr 26, 2026 1:31pm · Source: massive.com